Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term cyclophosphamide. Found 33 abstracts

no pagination
Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA. Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer. 2015 Apr;121(7):1032-9.   PMCID: PMC5531172
Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS, Spirtos NM. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. GYNECOLOGIC ONCOLOGY. 2006 Sep;102(3):432-9.
Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, Ansar R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY. 2006 May;24(13):2038-43.
Ozols RF, Bookman MA, Young RC, Du Bois A, Pfisterer J, Reuss A. Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. GYNECOLOGIC ONCOLOGY. 2006 Oct;103(1):1-6.
Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology. 2004 Jan;67 (5-6):390-6.
Garcia AA, Bookman MA, Rodriguez-Rodriguez L, Mutch DG, Look KY. Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies - A Gynecologic Oncology Group study. Investigational New Drugs. 2002 Nov;20(4):383-7.
Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. New England Journal of Medicine. 2000 Apr 13;342(15):1069-76.
McGuire WP, Brady MF, Ozols RF. The Gynecologic Oncology Group experience in ovarian cancer. Annals of Oncology. 1999 Jan;10:29-34.
Ozols RF. Chemotherapy for ovarian cancer: Beyond paclitaxel plus carboplatin. Cancer Journal from Scientific American. 1999 Nov;5(6):336-8.
Ozols RF. Paclitaxel plus carboplatin in the treatment of ovarian cancer. Seminars in Oncology. 1999 Feb;26(1):84-9.
Ozols RF, Gore M, Trope C, Grenman S. Intraperitoneal treatment and dose-intense therapy in ovarian cancer. Annals of Oncology. 1999 Jan;10:59-64.
Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: Primary and interval cytoreductive surgery. Seminars in Oncology. 1998 Jun;25(3):326-34.
McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Seminars in Oncology. 1998 Jun;25(3):340-8.
Schilder RJ, Shea TC. Multiple cycles of high-dose chemotherapy for ovarian cancer. Seminars in Oncology. 1998 Jun;25(3):349-55.
Fowble B. Postmastectomy radiation - A modest benefit prevails for high risk patients. Cancer. 1997 Mar 15;79(6):1061-6.
Ozols RF. Future directions in the chemotherapy of ovarian cancer. Seminars in Oncology. 1997 Oct;24(5):86-90.
Ozols RF, Vermorken JB. Chemotherapy of advanced ovarian cancer: Current status and future directions. Seminars in Oncology. 1997 Feb;24(1):S1-S9.
Bookman MA, McGuire WP, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, Odwyer P, Rowinsky E, Gallion HH, Ozols RF. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group. Journal of Clinical Oncology. 1996 Jun;14(6):1895-902.
Ozols RF. Paclitaxel (Taxol(R)) plus carboplatin as first-line treatment for advanced ovarian cancer. International Journal of Gynecological Cancer. 1996 Jan;6:9-12.
Kotz KW, Schilder RJ. High-Dose Chemotherapy and Hematopoietic Progenitor-Cell Support for Patients with Epithelial Ovarian-Cancer. Seminars in Oncology. 1995 Jun;22(3):250-62.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term cyclophosphamide

cyclophosphamide cisplatin carboplatin carcinoma randomized trial gynecologic-oncology-group doxorubicin paclitaxel chemotherapy bone-marrow transplantation phase-iii stage-iii platinum Oncology platinum-resistant phase-ii infusion vincristine phase-i survival Obstetrics & Gynecology ovarian cancer support oncology-group colony-stimulating factor randomized-trial cancer combination chemotherapy 2nd-line therapy rescue therapy gemcitabine phase- positive breast-cancer placebo-controlled trial clinical-trial breast-cancer Male term follow-up axillary and prednisone (R-CHOP) Female paclitaxel taxol responses comparing cisplatin taxanes remission ii paclitaxel-resistant 2nd- epithelial ovarian-cancer phase-iii trial taxol early stage zoledronic acid adenocarcinoma chemotherapy regimens Adult Chemoradiotherapy single-agent carboplatin Middle Aged intensive therapy early stage EOC 80 and over Aged stage-iii ovarian intergroup trial dose intensity prostate-cancer topoisomerase-i inhibitors phase-ii trial 1st-line treatment p-32 transplantation mortality nonsmall cell lung hexamethylmelamine consolidation new drugs Follow-Up Studies peripheral stem cell nodes autologous bone marrow transplantation Prospective Studies look laparotomy solid susceptibility gene Prednisone high-dose mitoxantrone blood progenitor cells gefitinib consolidation therapy tumors thiotepa platinum-resistant disease selection Prognosis intravenous Rituximab Antineoplastic Combined Chemotherapy Protocols bone-marrow follow-up radiotherapy lung carcinoma cost analysis-secondary bone neoplasms-retrospective study Monoclonal Antibodies-Murine-Derived intraperitoneal therapy etoposide peripheral-blood regimen Large B-Cell Lymphoma-Diffuse regional recurrence impact pharmacokinetics Doxorubicin Vincristine clinical-trials pamidronate leucovorin phase-i-ii radiation mastectomy Aged neoplasm trial drug therapy intensity analysis debulking surgery Neoplasm Staging Survival Rate therapeutic use administration & dosage ribonucleotide reductase dose Gynecologic Oncology Group (GOG) protocols Cyclophosphamide recurrent adjuvant postoperative radiotherapy recurrence rate phase-ii-trial cell support adjuvant chemotherapy mutations
Last updated on Monday, July 06, 2020